These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 21854134

  • 1. Recurrent preterm birth in women treated with 17 α-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy.
    Coleman S, Wallace L, Alexander J, Istwan N.
    J Matern Fetal Neonatal Med; 2012 Jul; 25(7):1034-8. PubMed ID: 21854134
    [Abstract] [Full Text] [Related]

  • 2. Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery.
    Gonzalez-Quintero VH, Cordova YC, Istwan NB, Tudela F, Rhea DJ, Romary LM, Marimon A, Desch CN, Stanziano GJ.
    Am J Obstet Gynecol; 2011 Sep; 205(3):275.e1-5. PubMed ID: 22071063
    [Abstract] [Full Text] [Related]

  • 3. Women receiving 17-alpha-hydroxyprogesterone caproate hospitalized for preterm labor at less than 34 weeks benefit from daily perinatal nursing surveillance.
    Rittenberg C, Sullivan S, Istwan N, Rhea D, Stanziano G, Newman R.
    Am J Obstet Gynecol; 2008 Oct; 199(4):389.e1-4. PubMed ID: 18928983
    [Abstract] [Full Text] [Related]

  • 4. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention.
    Joy S, Rhea DJ, Istwan NB, Desch CN, Stanziano G.
    Am J Perinatol; 2010 Apr; 27(4):343-8. PubMed ID: 20013580
    [Abstract] [Full Text] [Related]

  • 5. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA, Esplin MS, Biggio J, Bukowski R, Parry S, Zhang H, Huang H, Varner MW, Andrews W, Saade G, Sadovsky Y, Reddy UM, Ilekis J, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Genomics and Proteomics Network for Preterm Birth Research (GPN-PBR).
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [Abstract] [Full Text] [Related]

  • 6. 17-alphahydroxyprogesterone caproate in women with previous spontaneous preterm delivery: does a previous term delivery affect the rate of recurrence?
    Barton JR, Barton LA, Istwan NB, Rhea DJ, Desch CN, Sibai BM.
    Am J Obstet Gynecol; 2011 Sep; 205(3):269.e1-6. PubMed ID: 22071060
    [Abstract] [Full Text] [Related]

  • 7. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?
    How HY, Barton JR, Istwan NB, Rhea DJ, Stanziano GJ.
    Am J Obstet Gynecol; 2007 Sep; 197(3):260.e1-4. PubMed ID: 17826411
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pregnancy outcomes of women receiving compounded 17 α-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011.
    Sibai BM, Istwan NB, Palmer B, Stanziano GJ.
    Am J Perinatol; 2012 Sep; 29(8):635-42. PubMed ID: 22576126
    [Abstract] [Full Text] [Related]

  • 11. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
    Manuck TA, Stoddard GJ, Fry RC, Esplin MS, Varner MW.
    Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
    [Abstract] [Full Text] [Related]

  • 12. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
    González-Quintero VH, Istwan NB, Rhea DJ, Smarkusky L, Hoffman MC, Stanziano GJ.
    J Matern Fetal Neonatal Med; 2007 Mar; 20(3):249-52. PubMed ID: 17437227
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate.
    Ventolini G, Duke J, Po W, Barhan S, Rhea D, Desch C, Istwan N, Stanziano G.
    J Reprod Med; 2008 Sep; 53(9):667-71. PubMed ID: 18839818
    [Abstract] [Full Text] [Related]

  • 18. The prediction of recurrent preterm birth in patients on 17-alpha-hydroxyprogesterone caproate using serial fetal fibronectin and cervical length.
    Romero J, Rebarber A, Saltzman DH, Schwartz R, Peress D, Fox NS.
    Am J Obstet Gynecol; 2012 Jul; 207(1):51.e1-5. PubMed ID: 22595378
    [Abstract] [Full Text] [Related]

  • 19. The effect of 17α-hydroxyprogesterone caproate on preterm birth in women with an ultrasound-indicated cerclage.
    Rafael TJ, Mackeen AD, Berghella V.
    Am J Perinatol; 2011 May; 28(5):389-94. PubMed ID: 21380984
    [Abstract] [Full Text] [Related]

  • 20. The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage.
    Rebarber A, Cleary-Goldman J, Istwan NB, Rhea DJ, Desch C, Russo-Stieglitz K, Saltzman DH.
    Am J Perinatol; 2008 May; 25(5):271-5. PubMed ID: 18401840
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.